nalbuphine sold brand names nubain among others opioid analgesic used treatment given injection vein muscle side effects nalbuphine include sedation sweatiness clamminess nausea vomiting dizziness vertigo dry mouth unlike opioids little capacity cause euphoria respiratory also little incidence dysphoria dissociation hallucinations related side effects typical therapeutic nalbuphine mixed agonistantagonist opioid specifically acts moderateefficacy partial agonist antagonist μopioid receptor mor highefficacy partial agonist κopioid receptor kor whereas relatively low affinity δopioid receptor dor sigma nalbuphine patented introduced medical use united states marketed many countries throughout nalbuphine indicated relief moderate severe pain also used supplement balanced anesthesia preoperative postoperative analgesia obstetrical analgesia labor delivery however cochrane systematic review concluded included studies limited evidence demonstrate mgkg nalbuphine compared placebo might effective postoperative analgesic pain treatment research therefore needed compare nalbuphine postoperative although nalbuphine possesses opioid antagonist activity evidence nondependent patients antagonize opioid analgesic administered concurrently injection therefore patients receiving opioid analgesic general anesthetics phenothiazines tranquilizers sedatives hypnotics cns depressants including alcohol concomitantly nalbuphine may exhibit additive effect combined therapy contemplated dose one agents reduced addition relief pain drug studied treatment morphine induced pruritus itching pruritus common side effect morphine pure mor agonist opioid administration kjellberg et al published review clinical trials relating prevalence morphine induced pruritus pharmacologic control authors state nalbuphine effective antipruritic agent morphine induced pruritus effect may mediated via central nervous system mechanisms pan summarizes evidence activation pharmacological level kor antagonizes various mormediated actions brain author states neural mechanism potentially general morantagonizing function kor may broad applications treatment central nervous system mediated diseases state however nalbuphines pharmacological mechanism action pruritus result interaction two opioid receptors morphine induced pruritus syndrome may also caused release histamine mast cells skin gunion et al paus et al report mors kors located skin nerves keratinocytes levy et al reviewed literature relationship opioid mediated histamine release cutaneous mast cells etiology hypotension flushing pruritus authors investigated relative abilities various opioids induce histamine release mediated increased capillary permeability tissue edema wheal response cutaneous vasodilatation local redness flare response subjects intradermally injected ml equimolar concentrations x nalbuphine produce either wheal flare response nalbuphine available two concentrations mg mg nalbuphine hydrochloride per ml strengths contain sodium citrate hydrous citric acid anhydrous sodium metabisulfite mixture methylparaben propylparaben preservatives ph adjusted necessary hydrochloric acid mgml strength contains sodium chloride drug also available sulfite parabenfree formulation two concentrations mg mg nalbuphine hydrochloride per ml one ml strength contains sodium citrate hydrous citric acid anhydrous ph adjusted necessary hydrochloric acid mgml strength contains sodium chloride investigational extendedrelease oral formulation development trevi therapeutics like pure mor agonists mixed agonistantagonist opioid class drugs cause side effects initial administration drug lessens time tolerance particularly true side effects nausea sedation cognitive symptoms jovey et al side effects many instances ameliorated avoided time drug initiation titrating drug tolerable starting dose desired therapeutic dose important difference nalbuphine pure mor agonist opioid analgesic drugs ceiling effect respiration ceiling analgesic effect respiratory depression potentially fatal side effect use pure mor agonists nalbuphine limited ability depress respiratory function gal et al reported current nubain package insert frequent side effect patients treated nalbuphine sedation less frequent reactions feeling sweatyclammy nauseavomiting dizzinessvertigo dry mouth headache adverse reactions may occur reported incidence less possible rare side effects include speech difficulty urinary urgency blurred vision flushing warmth cochrane systematic review schnabel et al concluded due limited data analysis adverse events children treated nalbuphine compared opioids placebo postoperative pain could definitively case overdose adverse reaction immediate intravenous administration naloxone narcan specific antidote oxygen intravenous fluids vasopressors supportive measures used indicated nalbuphine semisynthetic mixed agonistantagonist opioid modulator phenanthrene morphinan series structurally related widely used opioid antagonists naloxone naltrexone potent opioid analgesic oxymorphone nalbuphine binds high affinity mor relatively low affinity behaves moderateefficacy partial agonist mixed agonistantagonist mor highefficacy partial agonist nalbuphine weak affinity sigma receptors eg ki nalbuphine said morphinelike lower doses however higher doses produces sedation drunkenness dysphoria effects effects include sedation dizziness vertigo lightheadedness anxiety dysphoria euphoria confusion hallucinations depersonalization unusual dreams feelings unreality nalbuphine potent analgesic analgesic potency essentially equivalent morphine milligram basis based relative potency studies using intramuscular administration beaver et al oral administered nalbuphine reported three times potent codeine okun et al clinical trials studied single dose experimental oral immediate release nalbuphine tablets analgesic efficacy four sixhour time period following administration nalbuphine mg range similar analgesic effects immediate release codeine mg range kantor et al sunshine et al schmidt et al reviewed preclinical pharmacology nalbuphine reported comparative data relative types opioid compounds authors point nalbuphine moiety approximately ten times pharmacologically potent mixed opioid agonistantagonist butorphanol antagonist index scale quantitates drugs ability act analgesic via opioid kor agonism well mor antagonist opioid antagonist activity nalbuphine onefourth potent nalorphine times pentazocine onset action nalbuphine occurs within minutes intravenous administration less minutes following subcutaneous intramuscular injection elimination halflife nalbuphine approximately hours average clinical studies duration analgesic activity reported range hours nalbuphine derivative morphine also known nalbuphine first synthesized introduced medical use united states search opioid analgesics less abuse potential pure mor agonist opioids number semisynthetic opioids developed substances referred mixed analgesics nalbuphine belongs group substances mixed agonistsantagonists drug class exerts analgesic actions agonistic activity kor drugs class possess mor antagonistic activity leading less abuse potential nalbuphine approved drug mixed class listed terms pharmacological actions selectivities opioid receptors mor partial agonist antagonist well kor agonist gustein et al nubain approved marketing united states remains opioid analgesic type marketed us controlled controlled substances act csa controlled substances act csa enacted nalbuphine placed schedule ii endo laboratories inc subsequently petitioned dea exclude nalbuphine schedules csa receiving medical scientific review scheduling recommendation department health education welfare forerunner department health human services nalbuphine removed schedule ii csa presently nalbuphine controlled substance csa nalbuphine hcl currently available injectable us european union nubain astra usa brand name injectable nalbuphine hcl discontinued marketed united states commercial reasons federal register however commercial suppliers provide generic injection formulation nalbuphine market nalbuphine marketed primarily brand names nubain nalpain also marketed brand name nalufin egypt raltrox bangladesh opsonin pharma limited brand name rubuphine india rusan healthcare pvt ltd brand name kinz nalbin pakistan sami global pharmaceuticals brand name analin medicaids pakistan brand name exnal indus pharma pakistan among many unlike many opioids nalbuphine limited potential euphoria accordance rarely whereas mor agonists produce euphoria mor antagonists kor agonists like nalbuphine moreover actually produce nalbuphine initially designated schedule ii controlled substance united states along opioids upon introduction controlled substances however manufacturer endo laboratories inc petitioned food drug administration remove schedule ii medical scientific review nalbuphine removed completely controlled substances act controlled substance united states comparison mor full agonists schedule ii united states whereas mixed kor mor agonistsantagonists butorphanol pentazocine schedule iv united canada opioids classified schedule nalbuphine butorphanol listed schedule iv httpsenwikipediaorgwikinalbuphine